Vinay Prasad: key facts
- Kind of voice
- Academic
- Role
- Chief Medical and Scientific Officer and Center for Biologics Evaluation and Research Director
- Quoted on
- Rare diseases, Elderly care & frailty
- Tracked press citations
- 5
- Most recently quoted
- 4 Oct 2026
- First quoted
- 30 Sept 2026
“He got a tremendous amount accomplished within his one-year sabbatical from UCSF and will be returning back to his academic home later next month”
What Vinay Prasad has said
“said the company should have compared its shot to a high-dose flu vaccine recommended for seniors rather than a standard-dose brand”
FDA vaccine chief · Elderly care & frailty · 30 Sept 2026 · First-of-its-kind flu vaccine could be coming as FDA panel weighs historic shot ↗
“Designing treatments unique to individual patients has always been the promised goal of personalised medicine. After 25 years the FDA has, for the first time, outlined a framework to facilitate these approvals. The Plausible Mechanism Framework is a revolutionary advance in regulatory science.”
Chief Medical and Scientific Officer and Center for Biologics Evaluation and Research Director · Rare diseases · 30 Sept 2026 · US FDA launches ultra-rare diseases framework ↗
“FDA official Vinay Prasad, M.D., who leads the agency's Center for Biologics Evaluation and Research overseeing gene therapies, is stepping down at the end of April.”
FDA official who leads the agency's Center for Biologics Evaluation and Research · Rare diseases · 30 Sept 2026 · Rare disease drug sales to surge past $400B by 2032 despite FDA volatility: Evaluate report ↗
“Vinay Prasad, M.D., a hematologist who oversaw the FDA department at the time of Ebvallo's January rejection, left the agency at the end of April.”
M.D., hematologist who oversaw the FDA department · Rare diseases · 30 Sept 2026 · FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next? ↗
Where Vinay Prasad has been quoted
- Trump administration’s embattled FDA vaccine chief departing for the second timetheguardian.com · 4 Oct 2026
- First-of-its-kind flu vaccine could be coming as FDA panel weighs historic shotnypost.com · 30 Sept 2026
- US FDA launches ultra-rare diseases frameworkpmlive.com · 30 Sept 2026
- Rare disease drug sales to surge past $400B by 2032 despite FDA volatility: Evaluate reportfiercepharma.com · 30 Sept 2026
- FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?fiercepharma.com · 30 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.